PF 06826647

Drug Profile

PF 06826647

Alternative Names: PF-06826647

Latest Information Update: 16 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pfizer
  • Class Anti-inflammatories; Antipsoriatics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Plaque psoriasis

Most Recent Events

  • 14 Jul 2017 Phase-I clinical trials in Plaque psoriasis in USA (PO) (NCT03210961)
  • 12 Jul 2017 Pfizer plans a phase I trial of PF 06826647 for Plaque psoriasis (PO) in July 2017 (NCT03210961)
  • 12 Jul 2017 Preclinical trials in Plaque psoriasis in USA (PO, Tablet, Suspension) (NCT03210961)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top